Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison

IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks successful a video league lasting astir 30 minutes.

Mr. Harrison discussed:

• How the institution is processing tissue-regeneration exertion for coiled care, aesthetics, oral health, veterinary medicine and reconstruction.

• Why wide weight-loss cause usage is driving request for treatments that reconstruct mislaid facial and assemblage volume.

• Conexeu aims to code large-volume insubstantial restoration, an country existent fillers and injectables bash not adequately serve.

• Focus connected 1 halfway exertion intended to enactment aggregate aesculapian applications, improving improvement efficiency.

• The institution processing a bioresorbable regenerative scaffold arsenic a imaginable alternate to silicone bosom implants.

• Key upcoming catalysts with FDA 510(k) submission and review, further information publications, bosom programme advancement and enlargement into dental and veterinary markets.

WATCH MORE

Beyond Mega IPOs: ICR Capital President & Chairman Don Duffy, Live from NYSE

About Conexeu Sciences Inc. (Nasdaq: CNXU)

Architecting bioregeneration. Conexeu Sciences is simply a preclinical-stage regenerative insubstantial level company. Our patented bioregenerative extracellular matrix (ECM) platform, CXU, is built connected a azygous structural principle: 1 formula, 1 device, designed to standard crossed aggregate addressable markets.

Conexeu is targeting large, multi-billion-dollar extremity markets, including coiled care, periodontal applications, and facial and assemblage insubstantial restoration, including the insubstantial changes that tin travel GLP-1 value loss, with further enlargement opportunities successful 3D printing and biofabrication workflows and the veterinary market. The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission successful aboriginal 2027 for its archetypal indication, taxable to regulatory review.

Conexeu is led by an experienced enactment squad with heavy expertise successful biomaterials, regenerative medicine, and aesculapian instrumentality commercialization and development.

WATCH MORE

Delivering Measurable AI Strategies: ICR CEO Anton Nicholas, Live astatine Nasdaq

About Miles Harrison

Miles Harrison is simply a 30-year planetary healthcare person processing and gathering category-defining brands. Current committee subordinate of Castle Biosciences (Nasdaq: CSTL), a precision diagnostics company.

8-Figure Exit, Novaestiq Corp. Co-Founder and CEO, built the "next-generation" aesthetics platform, raised $10M+ pre-Series A, and FDA approved successful September 2025.